PK of ARVs in pregnancy: rilpivirine, etravirine and raltegravir

Pharmacokinetics in pregnancy: darunavir/r and etravirine

Low prolactin and high 20alpha-HSD might contribute to ART-associated progesterone deficits in pregnancy

Pregnancy rates among women using ART and hormonal contraceptives in Kenya

Adolescents at increased risk of vertical transmission and poor pregnancy outcome in South Africa

Three drug ART best for preventing vertical transmission to infants: results from the PROMISE study

3 in 5 breastfeeding women with viral load >1,000 copies/mL are undiagnosed in Kenya, Malawi and South Africa

Point of care HIV PCR test for infant diagnosis: good performance but poorer results in youngest age group

Drug resistance in children after PMTCT and early treatment

Three drug regimen superior for preventing vertical transmission in the PROMISE study

Increased risk of ART-related hepatotoxicity in HIV positive pregnant women

Darunavir pharmacokinetics in pregnancy and postpartum

Good management of HIV positive pregnant women in UK – with some room for improvement

Pregnancy a risk factor for poor antiretroviral treatment outcomes in South African adolescents

Reasons for loss to follow up in the Malawi Option B+ programme

BHIVA pregnancy guidelines: 2014 interim update

Raltegravir pharmacokinetics in pregnancy and neonates

Efavirenz pharmacokinetics among pregnant women with and without tuberculosis coinfection

Pregnancy outcomes in Zambia

Uptake of ART is influenced by distance to the health facility in rural Zambia

Pharmacokinetics of antiretrovirals in pregnancy

Better virologic outcomes with efavirenz vs lopinavir/ritonavir in pregnant women and no difference in risk of preterm birth

HIV related infections remain the leading cause of maternal deaths in South Africa despite the availability of ART

Lower newborn bone mineral content with maternal tenofovir use

High rates of pregnancy in HIV positive women in Zambia and South Africa

HIV exposed vs unexposed babies have lower gestational age and birth weight in Danish study

Outcomes in infants exposed to lopinavir/ritonavir in utero

Two percent rate of efavirenz discontinuation in an ART programme in Malawi

Data from two cases of rilpivirine use in pregnancy

Raltegravir safe and effective in pregnancy in small French study

Side effects common but mostly mild in women taking higher dose protease inhibitors in pregnancy

Comparable efficacy and pregnancy outcomes with boosted atazanavir and lopinavir at standard doses

PrEP gives little extra benefit in attempted conception if male partner is on ART

Vertical transmission continues to decline in UK and Ireland

Decline in late preterm delivery with vaginal birth in Europe

High loss to follow up among asymptomatic women starting ART in pregnancy in Option B+

Decreased growth in ART exposed uninfected infants in Botswana

Transplacental transfer of atazanavir and neonatal hyperbilirubinaemia

Tenofovir population pharmacokinetics in pregnancy

Small increase in birth defects in the French Perinatal Cohort

Uptake and retention in Malawi’s Option B+ programme

Optimising ART initiation in pregnancy through linkage of services vs integration of ART into antenatal care

Safety of transplacental raltegravir in neonates and washout pharmacokinetics

Lopinavir/ritonavir in pregnancy: results from a systematic review

Possible mechanisms for adverse pregnancy outcomes in HIV positive women

The American Academy of Pediatrics recommends that HIV positive mothers not breastfeed their infants, regardless of maternal viral load and ART

The challenge of adherence during pregnancy and after

Tenofovir prophylaxis for neonates

New UK guidelines: Management of HIV infection in pregnant women (2012)

Darunavir use during pregnancy

Dolutegravir studies continue to show promise

Similar efficacy and a few gender related differences in side effects with rilpivirine vs efavirenz at 96-weeks

Poorer adherence and loss to follow up in Kenyan women who are pregnant when enrolled to ART programmes

Transplacental transfer of raltegravir and delayed plasma clearance in preterm neonates

Increased risk of preterm delivery with protease inhibitor based HAART in Mma Bana

Efavirenz in pregnancy: update of systemic review and meta-analysis

AZT not equivalent to HAART to prevent mother-to-child transmission in a Botswana programme

Increased risk of HIV transmission to HIV negative partners during pregnancy

Pharmacokinetics of darunavir and fosamprenavir in pregnancy

Low birth weight and preterm delivery

Hormonal contraception and HIV transmission risk

Treating children previously exposed to single dose nevirapine: update on IMPAACT P1060 and NEVEREST

Initiation of ART during breastfeeding can induce multidrug resistance in infants

Atazanavir in pregnancy: 155 cases in London clinics

Atazanavir levels indicate need for higher dose during pregnancy

Post navigation